Clinical Trials

Leukemia, Myeloid, Acute

NCT03471260 2026-03-11

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

Phase 1/2 Recruiting

96 enrolled

Phase 2 Not yet recruiting

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT07463768 2026-03-11

MIVONU

60 enrolled

Leukemia, Myeloid, Acute

NCT06707493 2026-03-10

Ivosidenib as Post-HSCT Maintenance for AML

75 enrolled

Leukemia, Myeloid, Acute

NCT07392242 2026-03-06

A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia

45 enrolled

Phase 1/2 Active not recruiting

Leukemia, Myeloid, Acute

NCT02677922 2026-02-19

A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

130 enrolled 38 charts

Leukemia, Leukemia, Myeloid, Acute

NCT06181734 2026-02-10

CONFIDHENCE

Completed

8 enrolled

Leukemia, Myeloid, Acute

NCT05010772 2026-01-14

Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

Phase 1 Recruiting

125 enrolled

Leukemia, Myeloid, Acute

NCT04493164 2025-11-21

CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

30 enrolled

Phase 3 Active not recruiting

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT03173248 2025-11-10

AGILE

146 enrolled 11 charts 2 FDA

Leukemia, Leukemia, Myeloid, Acute

NCT07131059 2025-08-20

MRD-positive AML Clinical Study

Phase NA Recruiting

120 enrolled

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT02074839 2025-06-08

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Phase 1 Recruiting

291 enrolled 6 FDA

Phase 2 Active not recruiting

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT03503409 2025-05-18

IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome

68 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05401097 2025-05-14

IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

125 enrolled

Phase 1 Active not recruiting

Leukemia, Myeloid, Acute

NCT02632708 2025-04-11

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

153 enrolled

Leukemia, Myeloid, Acute

NCT05907057 2025-04-11

An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.

Phase 3 Recruiting

245 enrolled

Phase 1 Active not recruiting

Leukemia, Myeloid, Acute

NCT04250051 2025-01-13

Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia

2 enrolled

Phase 3 Active not recruiting

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT03839771 2024-10-02

HOVON150AML

968 enrolled

Leukemia, Myeloid, Acute

NCT04176393 2023-02-13

A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation

Phase 1 Completed

30 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT04655391 2022-06-09

Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation

Phase 1 Withdrawn

Leukemia, Myeloid, Acute

NCT04044209 2022-01-20

A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

Phase 2 Withdrawn

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03245424 2018-07-24

Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation

Approved for marketing